SBIR/STTR Research Award

APTAMER SCREENING FOR BIOTERRORISM AGENT THERAPEUTICS

Award identifier 54bb1c766c56bdaef118cd6a113f4edfd9f983cab2149d6298f544401343741cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$198,755

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CYNTELLECT, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Combinatorial selection and structure-based design methods are currently being used to develop a novel therapeutic strategy to modulate the differential expression of key proteins in response to potential bioterrorism (BT) pathogens under a DARPA-funded program at University of Texas-Medical Branch (UTMB). Proprietary phosphorothioate- or phosphorodithioate-modified duplex DNA decoys (i.e., thioaptamers) can modulate host proteomes, particularly the immune response cytokines and key transcription factors such as NF-KB, during challenge with BT pathogens. UTMB results showed specific interactions between thioaptamers and NE-KB dirners with concomitant influences on animal survival in a model of arenavirus-induced hemorrhagic fever, a potential bioterrorism threat. Cell-free and in vivo assays are available for measuring aptamer effectiveness, but presently all aptamer combinatorial library selection is performed in vitro using a cell-free recombinant protein system. A cell-based in vitro screening model would have significant value because of the greater throughput potential (as compared to in vivo models) and the more physiological response (as compared to cell-free assays). However, some key challenges to such a model have arisen: the ability to (i) efficiently deliver thioaptamers into cells, (ii) identify cells having taken up aptamer, and (iii) follow significant numbers of these cells in vitro following thioaptamer delivery and BT pathogen challenge. Additionally, biosafety containment concerns are associated with the manipulation of contaminated cells. Oncosis has developed a laser-based system for high-speed in situ cell scanning and manipulation. The system scans cells at >105 per second and laser-irradiates specific individual cells at >103 per second within a sealed container. Laser irradiation of specific cells can lead to various outcomes, including cell death (leading to cell purification), photochemical activation, optoinjection. etc. Optoinjection is a versatile procedure for loading cells with a variety of substances (e.g. plasmids. proteins, etc.), whereby a laser is used to increase the cell membrane permeability, allowing the substance to enter the cell. The increased permeability is transient, and the cells are otherwise unharmed. It is hypothesized that the optoinjection and high-throughput in situ scanning capabilities of the LEAP platform could be used to overcome the three key challenges in thioaptamer screening described above. The LEAP platform therefore represents an improved methodology to safely manipulate and assay infected cells within a closed-system platform, enabling thioaptamer screening in the Pichinde virus-infected macrophage as a model system.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.